Cellectar Biosciences, Inc. (CLRB) on Tuesday announced positive 12-month follow-up data from its Phase 2b CLOVER WaM study evaluating iopofosine I 131 in patients with Waldenström acroglobulinemia, a rare, slow-growing blood cancer.
The updated dataset, which includes at least 12 months of follow-up for all enrolled patients as requested by the U.S. Food and Drug Administration, showed an overall response rate of 83.6%, while the major response rate reached 61.8%, meeting the study's primary endpoint.
Separately, the company said it has entered into securities purchase agreements with certain institutional investors and members of management to issue and sell up to $140 million in shares.
The financing is expected to support a confirmatory study and the filing of a New Drug Application seeking accelerated approval of iopofosine I 131 for the treatment of Waldenström macroglobulinemia with the FDA.
The company's shares were more than 80% up in pre-market trading after closing at $2.83 on Monday.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.